Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma

Burchill, Susan A.; Kinsey, Sally; Picton, Susan; Roberts, Paul; Pinkerton, CR; Selby, Peter J.; Lewis, Ian

doi:10.1002/1096-911x(20010101)36:1<213::aid-mpo1052>3.3.co;2-0

Cited by 12 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[43][44][45][46][47][48] We observed TH positivity in 48.9% of PBSC samples of children in the study cohort and Burchill et al 48 reported a similar rate of 50%. 48 In addition, the results of the current study and that of an earlier report show a higher prevalence of tumor cell dissemination in BM than in PBSC autografts. 44 Our study adds more data to the literature, documenting a high prevalence of tumor cell dissemination to autologous HSC products harvested from patients with neuroblastoma in clinical remission shortly after the completion of therapy.…”

Section: Discussionmentioning

confidence: 62%

“…42 However, there is the concern of tumor cell contamination of HSC products, either BM or PBSC, harvested from patients with metastastic tumors. [43][44][45][46][47][48] We observed TH positivity in 48.9% of PBSC samples of children in the study cohort and Burchill et al 48 reported a similar rate of 50%. 48 In addition, the results of the current study and that of an earlier report show a higher prevalence of tumor cell dissemination in BM than in PBSC autografts.…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase‐polymerase chain reaction

Tsang

Tsoi

et al. 2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe identification of neuroblastoma metastases to bone marrow (BM) is requisite in staging disease for risk‐adopted therapy. However, micrometastases were not elucidated fully.METHODSFlow cytometry (FCM) with CD45/CD56/CD81 and reverse transcriptase‐polymerase chain reactions (RT‐PCR) for tyrosine hydroxylase (TH) transcripts were used to evaluate neuroblastoma in bilateral BM aspirates at diagnosis, BM autografts, peripheral blood stem cell (PBSC) collections, and CD34+ cell products of 27 children.RESULTSTH transcripts were amplified in histology‐negative (H−) BM specimens from seven patients (four patients with Stage 3 disease, two with Stage 4 disease, and one with Stage 4S disease), revealing a prevalence of submicroscopic metastasis. The median number of CD45−CD81+CD56+ cells in four H− TH− BM samples from two patients with Stage 1 and Stage 2 disease, respectively, was comparable to that encountered in 10 normal BM controls (0.003% [range, 0.002–0.004%] vs. 0.004% [0–0.008%], P = 0.724). In six H− TH+ BM specimens from three patients whom were otherwise diagnosed with neuroblastoma Stage 3, 0.031% (0.009–0.06%) CD45−CD81+CD56+ cells were detected. Besides, 1.474% (0.088–3.009%) CD45−CD81+CD56+ cells were identified in four H− TH+ BM specimens from two patients at Stage 4. TH transcripts were evident in four of five BM autografts and in 22 of 45 (48.9%) PBSC specimens. FCM demonstrated 0.018% and 0.049% CD45−CD81+CD56+ cells in two TH+ BM autografts, respectively. The number of CD45−CD81+CD56+ cells was higher in 19 TH+ PBSC specimens than in 20 TH− PBSC specimens (0.026% [0.006–1.128%] vs. 0% [0–0.009%], P < 0.0001). CD34+ cell selection achieved 2.9 (2.1–3.5) log depletion of CD45−CD81+CD56+ cells in four manipulated products, rendering six of seven PBSC autografts TH‐free.CONCLUSIONSFCM in combination with RT‐PCR evaluated neuroblastoma micrometastasis and assessed the purity of hematopoietic autografts for transplant. However, the clinical relevance remains to be elucidated. Cancer 2003;97:2887–97. © 2003 American Cancer Society.DOI 10.1002/cncr.11389

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 66%

Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase‐polymerase chain reaction

Tsang

Tsoi

et al. 2003

Cancer

View full text Add to dashboard Cite

show abstract

“…Clinically significant disease has been detected in PB (Burchill et al, 1995(Burchill et al, , 2001aKuroda et al, 1997;Shono et al, 2000;Cheung et al, 2004) and BM (Miyajima et al, 1996;Kuroda et al, 1997;Shono et al, 2000;Fukuda et al, 2001;Horibe et al, 2001) samples from children with NB at diagnosis, on therapy, during follow-up and at relapse by RT -PCR for TH. Furthermore, this technique has been used to detect NB cells in PBSC from children with high-risk disease (Miyajima et al, 1996;Burchill et al, 2001b;Corrias et al, 2006). The success of TH as a target is in part attributed to the stability of the mRNA in haemopoietic compartments and its ubiquitous expression in NB cells; even those rare NB cells that do not secrete catecholamines express TH mRNA.…”

Section: Target Selection In Nbmentioning

confidence: 99%

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

et al. 2009

View full text Add to dashboard Cite

Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task Force has defined standardised methods for the determination of minimal disease (MD) by immunocytology (IC) and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) using disialoganglioside G D2 and tyrosine hydroxylase mRNA respectively. The INRG standard operating procedures (SOPs) define methods for collecting, processing and evaluating bone marrow (BM), peripheral blood (PB) and peripheral blood stem cell harvest by IC and QRT-PCR. Sampling PB and BM is recommended at diagnosis, before and after myeloablative therapy and at the end of treatment. Peripheral blood stem cell products should be analysed at the time of harvest. Performing MD detection according to INRG SOPs will enable laboratories throughout the world to compare their results and thus facilitate quality-controlled multi-centre prospective trials to assess the clinical significance of MD and minimal residual disease in heterogeneous patient groups.

show abstract

“…However, it has been shown that the presence of Ͼ100 NB cells of 10 5 BM hematopoietic cells at the end of induction therapy, as assessed by immunocytochemical analysis, and the presence of NB cells in the peripheral blood (PB) at diagnosis, as assessed by molecular analysis, are independent unfavorable prognostic factors in NB patients (4 -6). Similarly, increasing evidence suggests that NB relapses may be associated with peripheral blood stem cell (PBSC) contamination (7)(8)(9)(10), and gene-marked tumor cells present in BM grafts have been detected at relapse (11).…”

Section: Introductionmentioning

confidence: 99%

Detection of Neuroblastoma Cells in Bone Marrow and Peripheral Blood by Different Techniques

Corrias¹,

Faulkner

Pistorio

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma

Cited by 12 publications

References 0 publications

Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase‐polymerase chain reaction

Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase‐polymerase chain reaction

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

Detection of Neuroblastoma Cells in Bone Marrow and Peripheral Blood by Different Techniques

Contact Info

Product

Resources

About